Integrated Infrastructure Core Platforms
The development of an integrated portfolio of shared technology core platforms is a central aspect of the CRUK City of London Centre’s strategy. Building on the complementary strengths of the partners, we are developing a world-class infrastructure to support the CRUK CoL Centre’s scientific programme, deliver a step-change in capacity, and give the best value for money.
The TME core primarily supports the Developing Biological Therapies programme. The new infrastructure will be embedded within facilities across the CRUK City of London Centre.
Equipment available in the TME core:
• ZellScannerONE™ chipcytometry to enable cutting edge, multiparametric analysis of cell-to-cell variations within cell populations. A technician will be available to run the chipcytometry system. The scanner will be located at Barts Cancer Institute. See more details about the Zellscanner One Imaging Platform here. Contact: Joseph Hartlebury firstname.lastname@example.org
• A LSM 880 with Airyscan Fast confocal microscope at Barts Cancer Institute. See more details about the Zeiss LSM 880 Confocal Microscope with Airyscan Fast here. Contact: Linda Hammond email@example.com | +44 (0)20 7882 5132
• A small cabinet irradiator is available as part of a preclinical irradiation platform for focal delivery of radiotherapy, to model combination therapy with radiotherapy at UCL. Contact: Rebecca Carter firstname.lastname@example.org
Expertise available for the TME core:
The Centre will host 2 single cell specialists at the UCL Cancer Institute. The post will build links with the TME models team, identify data storage/analysis needs, generate protocols, and initiate pilot projects primarily aimed at single cell analysis of the TME in cancer samples. See more details about the Single Cell Genomics Facility here. Contact: Imran Uddin email@example.com | Gordon Beattie firstname.lastname@example.org
A 3D bioengineering specialist at the Barts Cancer Institute to identify collaboration opportunities with other Centre labs that are using these technologies, develop SOPs for multi-cell 3D human tumour models that can be used throughout the Centre and identify the need for new techniques. See more details about Human Tumour Microenvironment Models here. Contact: Mina Mincheva email@example.com
A Tcom PDX/iGEMM specialist who will complement the CITA-funded iGEMM core specialist, at the UCL Cancer Institute, to support development of facilities at Clare Hall, identify pilot project opportunities with the Crick and other partners, and generate relevant SOPs. See more details about Patient-Derived immune Xenograft Core here. Contact: Mansi Shah firstname.lastname@example.org
Expertise available for the Advanced Cellular Engineering Core
Equipment available for the Cell and Vector Manufacturing Core
Four isolators for vector manufacture to support development of cell therapies and clinical translation, with the aim of minimising immune-related toxicities in adult and paediatric cancer at KCL
Expertise available for the Cell and Vector Manufacturing Core
A GMP cell production specialist will be in the Centre for Cell, Gene & Tissue Therapeutics at the Royal Free Hospital. The specialist will initiate SOPs for pilot projects, primarily of CAR, TCR and TIL therapies in adult and paediatric cancers, as an initial enhancement of GMP manufacturing capacity.
An additional 1 GMP cell production specialist will be available at the Centre for Cell, Gene & Tissue Therapeutics at the Royal Free Hospital. Contact: Amaia Cadinanos Garai email@example.com.
Expertise available for the Advanced Antibody and Recombinant Protein Engineering Core
A mAb tech specialist, embedded within the Crick Institute team, will be available to support the imaging and therapeutics-focused projects that require mAb and protein products, and generate a production strategy. See more details about the Advanced Antibody Core here. Contact: Toni Rullan firstname.lastname@example.org.
The Imaging core primarily supports the Cross Disciplinary Approaches Enhancing Biotherapeutics programme in the CRUK City of London Centre.
This core utilises a diverse range of imaging modalities and inter-disciplinary approaches to explore how best to develop and use biological therapies. This includes imaging the distribution of biological therapies and imaging changes in tumour volume, perfusion, vascular structure, and tumour mechanics. Imaging modalities include MRI, PET, SPECT, microCT, and two-photon microscopy.
Equipment available at the Imaging and Image-Guided Therapy Core
A clinical spec 3T MRI scanner will be available into the research environment at UCL. This equipment will enable us to monitor tumour response to biotherapeutics and conventional therapies, and accelerate the translation of new protocols from the lab to the clinic.
A pre-clinical CT-guided irradiator at UCL. Contact: Rebecca Carter email@example.com
Expertise available for the Imaging and Image-Guided Therapy Core
A radiochemist/preclinical imaging specialist will be placed at KCL’s Department of Imaging Chemistry and Biology, to support the validation of radiolabelling methodology, and the preclinical evaluation of novel translatable PET/SPECT imaging agents and targeted radionuclide therapy. See more details about Imaging Chemistry and Biology here. Contact: Truc Pham firstname.lastname@example.org.
A Radiation Biologist will be placed at the UCL Cancer Institute to manage the pre-clinical CT-guided irradiator. Contact: Rebecca Carter email@example.com
A Biophysicist will be placed at the UCL Centre for Advanced Biomedical Imaging, to work with the radiation biologist on initial projects using the preclinical radiotherapy facility for optimising novel agents in combination with advanced focal radiotherapy. See more details about Imaging Patient Therapy Response here. Contact: Valenti Gomez firstname.lastname@example.org
- A Biochemist will be placed at KCL, working closely with the UCL Centre for Advanced Biomedical Imaging radiation biologist on initial projects using the preclinical radiotherapy facility for optimising novel agents in combination with advanced focal radiotherapy. Contact: Oskar Timmermand email@example.com
A Biological Models specialist will be placed at Barts Cancer Institute, to support development of tumour models and radiotracer distribution in conjunction with intrinsic MR-traceable contrast parameters. See more details about Three-Dimensional Imaging of Biological Tumour Models here. Contact: Laura Wisniewski firstname.lastname@example.org
A physicist will be placed at the KCL Biomedical Engineering Department, to adapt and validate MR elastography techniques for immune monitoring. Contact: Omar Darwish email@example.com
A Chemist will be placed at the UCL Department of Chemistry to initiate projects for development and validation of theranostic agents. Contact: Kirsten Hawkins firstname.lastname@example.org
- A MR Physicist will be placed at the UCL Institute of Neurology to initiate projects for development and validation of theranostic agents. See more details about Preclinical 9.4T Magnetic Resonance Imaging (MRI) here. Contact: Daniele Tolomeo email@example.com.
A centralised High Performance Computing (HPC) Cluster storage and processing units, supported by 2 HPC Technology Staff will be embedded within the UCL Department of Computing. Additionally, a specialist for data integration will be based at UCL. Contact: Tristan Clark firstname.lastname@example.org